Healthcare Finance >>>

    IT Cash Delays Foreshadowed Healthcare Exchange Woes

    By Peter Gosselin, senior health-care policy analyst, Bloomberg Government   Although the Affordable Care Act has been law for three and a half years, one third of the funds going to the top contractors working on the federal exchanges were awarded in the six months before the new insurance marketplaces opened Oct. 1, a Bloomberg [...]

    Obamacare Opponents May Change Tactics After Shutdown

    By Matt Barry, Bloomberg Government It is probably safe to say that it is unlikely opponents of President Obama’s health law will try to seek its demise by threatening another shutdown or pushing against the debt ceiling again. However, more targeted and strategic efforts to increase the scrutiny of the law’s implementation and target specific [...]

    ACL Surgery Worth The Price

    by Elizabeth Krutoholow Anterior cruciate ligament or ACL reconstruction is more cost-effective than rehabilitation for treating tears, a common knee injury, according to a recent cost-utility analysis. Dr. Richard Mather, assistant professor, department of Orthopaedic surgery, Duke University Medical Center and lead author of the study said the study may aid in treatment decisions for [...]

    Lilly May Lead Pharma 3Q EPS Growth As Astra, Merck Fall

    Sam Fazeli, Bloomberg Industries   Eli Lilly has had the largest increase in 2013 adjusted consensus EPS estimates across large pharma peers since the start of the third quarter. This was mostly driven by deep cost cutting and better than expected sales from drugs like Cymbalta. Read more >>> 

    Kinetic Concepts to Use Cash to Buy Back Bonds

    Kinetic Concepts plans to buy back $112 million of bonds due 2019 when it has excess cash provided that the debt trades at an attractive price, said Nathan Speicher, the issuer’s vice president of investor relations and treasury. Click HERE for more.

    BioPharma Adopting Adaptive Designs Earlier

    Contribution by Phil Birch, Ph.D., Senior Vice President, Global Strategic Marketing at Aptiv Solutions   Adaptive designs can bring substantial benefits to sponsor companies if adopted broadly at the portfolio level. For instance, available data indicate that futility stopping in Phase II and Phase III can save mid-size biopharma companies between $5 million and $10 [...]

    FDA May Decide on New Use For AbbVie’s Humira

    by Andrew Berens, Grace Guo, Bloomberg Industries   AbbVie’s supplemental Biologics License Application (sBLA) to expand Humira’s existing approval for ankylosing spondylitis to include the treatment of non-radiographic axial spondyloarthritis has an estimated PDUFA date of Sept. 29.   Read more>>>

    Boehringer Respimat May Challenge Glaxo, Novartis in Respiratory Disease

    By Sam Fazeli, Bloomberg Industries   Boehringer Ingelheim may join Novartis in challenging GlaxoSmithKline’s dominance in the treatment of respiratory diseases with new safety data on its Respimat device. While the data may not stave off generic competition for one of its top-selling drugs, Spiriva, it may allow Boehringer to develop a competitive combination therapy. [...]

    Roche May Be First to Dry-AMD Market With Biomarker Focus

    by Elizabeth Krutoholow   Roche may be able to overtake Otsuka in the race to market in geographic atrophy (GA), by leveraging a biomarker test for lampalizumab to structure a smaller pivotal trial, or to garner a breakthrough designation with the FDA, according to Bloomberg Industries. The company will update investors on plans later this [...]

    Onyx Takeover May Intensify Interest in Oncology Drug Companies

    by Andrew Berens, MD & Thomas Smith, Bloomberg Industries   Amgen’s $10.4 billion purchase of Onyx demonstrates an appetite among biotech and pharma for companies with commercialized products and an oncology pipeline. Other oncology-focused biotechs with at least one commercialized product include Incyte, Seattle Genetics, Medivation and Ariad, each with a market value of $3 [...]

Bloomberg BRIEF Newsletters